Aerpio Pharmaceuticals
Cincinnati, Ohio, United States of America
About Aerpio:
Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases.
Our lead product candidate, AKB-9778, is a Tie2 activator being developed for the treatment of diabetic eye disease. AKB-9778 is currently in a Phase 2b study (TIME-2b) for the treatment of non-proliferative diabetic retinopathy (NPDR), a disease that affects millions of people across the globe.
Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases.
Our lead product candidate, AKB-9778, is a Tie2 activator being developed for the treatment of diabetic eye disease. AKB-9778 is currently in a Phase 2b study (TIME-2b) for the treatment of non-proliferative diabetic retinopathy (NPDR), a disease that affects millions of people across the globe.
Quick Links
- 50 Division Street, Suite 501,
- Somerville, NJ 08876
- support@emedevents.com